Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
Magnani CF, Mezzanotte C, Cappuzzello C, Bardini M, Tettamanti S, Fazio G, Cooper LJN, Dastoli G, Cazzaniga G, Biondi A, Biagi E. Magnani CF, et al. Among authors: dastoli g. Hum Gene Ther. 2018 May;29(5):602-613. doi: 10.1089/hum.2017.207. Epub 2018 Apr 16. Hum Gene Ther. 2018. PMID: 29641322
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC, Buracchi C, Arcangeli S, Galimberti S, Valsecchi MG, Perriello VM, Rasko T, Alberti G, Magnani CF, Cappuzzello C, Lundberg F, Pande A, Dastoli G, Introna M, Serafini M, Biagi E, Izsvák Z, Biondi A, Tettamanti S. Rotiroti MC, et al. Among authors: dastoli g. Mol Ther. 2020 Sep 2;28(9):1974-1986. doi: 10.1016/j.ymthe.2020.05.021. Epub 2020 May 30. Mol Ther. 2020. PMID: 32526203 Free PMC article.
Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.
Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, Fazio G, Zaninelli S, Tettamanti S, Cesana S, Colombo V, Quaroni M, Cazzaniga G, Rovelli A, Biagi E, Galimberti S, Calabria A, Benedicenti F, Montini E, Ferrari S, Introna M, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, Biondi A. Magnani CF, et al. Among authors: dastoli g. J Clin Invest. 2020 Nov 2;130(11):6021-6033. doi: 10.1172/JCI138473. J Clin Invest. 2020. PMID: 32780725 Free PMC article. Clinical Trial.
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.
Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, Barbui T, Bernasconi C, Dastoli G, Fuga G, Gamba E, Gargantini L, Gattei V, Lauria F, Lazzarino M, Mandelli F, Morra E, Pulsoni A, Ribersani M, Rossi-Ferrini PL, Rupolo M, Tura S, Zagonel V, Zaja F, Zinzani P, Reato G, Foa R. Rambaldi A, et al. Among authors: dastoli g. Blood. 2002 Feb 1;99(3):856-62. doi: 10.1182/blood.v99.3.856. Blood. 2002. PMID: 11806987 Free article. Clinical Trial.
5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.
Palmeri S, Meli M, Danova M, Bernardo G, Leonardi V, Dastoli G, Rausa L, Russo A, Filippelli G, Palmieri G, Russo A, Della Vittoria Scarpati M, Lo Russo V, Di Lauro L, Colucci G, Bruni G, Piazzi M, Gebbia N, Spada S. Palmeri S, et al. Among authors: dastoli g. J Cancer Res Clin Oncol. 1998;124(3-4):191-8. doi: 10.1007/s004320050154. J Cancer Res Clin Oncol. 1998. PMID: 9619746 Clinical Trial.
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.
Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G; GISL. Sacchi S, et al. Among authors: dastoli g. Haematologica. 2001 Sep;86(9):951-8. Haematologica. 2001. PMID: 11532623 Free article. Clinical Trial.
28 results